Roche’s Alecensa wins FDA approval for ALK-positive NSCLC
The approval was based on results from Phase 3 ALINA study in which Alecensa lowered the risk of…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
22 Apr 24
The approval was based on results from Phase 3 ALINA study in which Alecensa lowered the risk of…
19 Apr 24
The regulator has authorised Entyvio as a maintenance drug for individuals with moderately to highly active Crohn's disease…
19 Apr 24
The pharma company is currently recruiting patients in the Phase 2 GenePHIT study to assess the safety and…
18 Apr 24
In both the late-stage trials, the drug reduced the AHI against the placebo and achieved a mean AHI…
18 Apr 24
The results of the final trial showed that Shingrix is effective against shingles with high vaccine efficacy rate…
17 Apr 24
The approval was based on findings from three clinical studies that demonstrated Nulibry's safety and effectiveness in MoCD…
17 Apr 24
According to the results, Imfinzi along with chemotherapy decreased the mortality risk by 26% versus chemotherapy alone at…
17 Apr 24
Vaccine candidate provides broad coverage against the five most common groups of bacteria causing invasive meningococcal disease and…
16 Apr 24
The multicentre, randomised, placebo-controlled APPLAUSE-IgAN trial recruited 518 adult patients with primary IgAN, who were given twice-daily doses…
04 Apr 24
The approval for Zevtera was based on the clinical efficacy and safety data from the Phase 3 ERADICATE…